Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts

Annals of Surgical Oncology

Volumn 23, Issue 1, 2016, Pages 305-311

  Read, Matthew ^a,b   Liu, David ^a,b   Duong, Cuong P ^a   Cullinane, Carleen ^a,b   Murray, William K ^a   Fennell, Christina M ^a,b   Shortt, Jake ^b,c,d   Westerman, David ^a,b   Burton, Paul ^e,f   Clemons, Nicholas J ^a,b   Phillips, Wayne A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c SOUTHERN HEALTH   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f CABRINI HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN RET; INTERLEUKIN 2 RECEPTOR;

ARTICLE; CANCER SURGERY; CANCER TRANSPLANTATION; CLINICAL ARTICLE; CRYOPRESERVATION; ENDOSCOPIC BIOPSY; ESOPHAGUS; ESOPHAGUS CANCER; HUMAN; HUMAN TISSUE; INTRAMUSCULAR TRANSPLANTATION; LOWER ESOPHAGUS SPHINCTER; MOUSE; NONHUMAN; PERITONEUM; TREATMENT RESPONSE; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; ANIMAL; ESOPHAGEAL NEOPLASMS; GRAFT SURVIVAL; INTRAMUSCULAR DRUG ADMINISTRATION; KNOCKOUT MOUSE; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; ESOPHAGEAL NEOPLASMS; GRAFT SURVIVAL; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASM TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84952628265     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4425-3     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
3. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–6.
4. SEER Cancer Statistics Factsheets: Esophageal Cancer. Bethesda, MD: National Cancer Institute. Available: http://seer.cancer.gov/statfacts/html/esoph.html. Accessed 5 Nov 2014.
5. Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.
6. Boonstra JJ, Tilanus HW, Dinjens WNM. Translational research on esophageal adenocarcinoma: from cell line to clinic. Dis Esophagus. DOI: 10.1111/dote.12095.
7. Dodbiba L, Teichman J, Fleet A, et al. Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Lab Invest. 2013;93:397–407.
8. Rumpel CA, Powell SM, Moskaluk CA. Mapping of genetic deletions on the long arm of chromosome 4 in human esophageal adenocarcinomas. Am J Pathol. 1999;154:1329–34.
9. Boonstra JJ, van Marion R, Douben HJ, et al. Mapping of homozygous deletions in verified esophageal adenocarcinoma cell lines and xenografts. Genes Chromosomes Cancer. 2012;51:272–82.
10. De Both NJ, Wijnhoven BPL, Sleddens HFBM, Tilanus HW, Dinjens WNM. Establishment of cell lines from adenocarcinomas of the esophagus and gastric cardia growing in vivo and in vitro. Virchows Arch. 2001;438:451–6.
11. El-Rifai W, Harper JC, Cummings OW, Hyytinen ER, Frierson HF Jr, Knuutila S, Powell SM. Consistent genetic alterations in xenografts of proximal stomach and gastro-esophageal junction adenocarcinomas. Cancer Res. 1998;58:34–37.
12. Zhang J, Jiang D, Li X, et al. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. Lab Invest. 2014; 94:917–26.
13. Wang Z, Da Silva TG, Jin K, et al. Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. Cancer Res. 2014;74:6364–74.
14. Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013.
15. Taniere P, Borghi-Scoazec G, Saurin JC, et al. Cytokeratin expression in adenocarcinomas of the esophagogastric junction: a comparative study of adenocarcinomas of the distal esophagus and of the proximal stomach. Am J Surg Pathol. 2002;26:1213–21.
16. Clemons NJ, Do H, Fennell C, Deb S, Fellowes A, Dobrovic A, Phillips WA. Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci. 2014;59:78–88.
17. Lieber J, Eicher C, Wenz J, Kirchner B, Warmann SW, Fuchs J, Armeanu-Ebinger S. The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer. 2011;11:362.
18. Wunderlich M, Mizukawa B, Chou F, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013;121:e90–7.
19. Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol. 1995;37:23–31.
20. Desgranges C, Razaka G, De Clercq E, Herdewijn P, Balzarini J, Drouillet F, Bricaud H. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. Cancer Res. 1986;46:1094–101.
21. Israely T, Dafni H, Granot D, Nevo N, Tsafriri A, Neeman M. Vascular remodeling and angiogenesis in ectopic ovarian transplants: a crucial role of pericytes and vascular smooth muscle cells in maintenance of ovarian grafts. Biol Reprod. 2003;68:2055–64.
22. Braunwald E. Regulation of the circulation. N Engl J Med. 1974;290:1420–5.
23. John T, Yanagawa N, Kohler D, et al. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. J Thorac Oncol. 2012;7:1101–8.
24. Chen K, Ahmed S, Adeyi O, Dick JE, Ghanekar A. Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One. 2012;7:e39294.
25. Vockerodt M, Yap LF, Shannon-Lowe C, Curley H, Wei W, Vrzalikova K, Murray PG. The Epstein-Barr virus and the pathogenesis of lymphoma. J Pathol. DOI: 10.1002/path.4459.